gefitinib approved for nsclc, atezolizumab shrinks bladder tumors, and more
Published 8 years ago • 2.9K plays • Length 4:48
Download video MP4
Download video MP3
Similar videos
-
1:27
fda approval of atezolizumab for nsclc
-
7:05
the fda approval of atezolizumab in bladder cancer
-
6:49
fda approval of atezolizumab for advanced bladder cancer
-
1:10
dr. steinberg on the fda approval of atezolizumab in bladder cancer
-
3:07
efficacy and safety of afatinib vs erlotinib and gefitinib in egfr nsclc
-
1:03
sangeetha palakurthi on fda approval of atezolizumab in nsclc
-
3:13
frontline atezolizumab for advanced bladder cancer
-
1:20
dr. rosenberg on future use of atezolizumab in bladder cancer
-
1:50
dr. melissa johnson on atezolizumab in patients with nsclc
-
8:30
fda approvals in bladder cancer, nsclc, aml, hcc, and a breakthrough designation in nsclc
-
1:28
dr. randy sweis on impact of atezolizumab approval in bladder cancer
-
1:25
dr. sonpavde on the next steps for atezolizumab in urothelial carcinoma
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
2:10
reconsideration of gefitinib in egfr-mutant nsclc
-
3:45
azd9291 and rociletinib in t790m-mutant nsclc
-
6:27
fda approval in nsclc, and ema regulatory advances in pancreatic cancer, nhl, and cll
-
4:41
upfront egfr-targeted therapy for nsclc
-
1:41
adjuvant atezolizumab in nsclc
-
6:50
novel agents in nhl, fda approval in myeloma, combination trials with atezolizumab, and more
Clip.africa.com - Privacy-policy